BAO PHARMA-B

2659
12.08015.71% ( +1.640 )
Delay Closed: Nov 16, 16:08:11

Overview

BAO PHARMA-B (2659)

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainl...

Open
10.010
High
12.080
Low
9.990
Prev. Close
10.440
Volume
6.74M
Turnover
75.40M
Avg Price
11.185
Bid/Ask Ratio
55.79%
Amplitude
20.02%
52wk High
206.000
Volume Ratio
11.46
Turnover Ratio
4.45%
52wk Low
6.475
HK Mkt Cap
1.83B
Market CapHKD
3.90B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.30
EPSDynamic
-1.09
EPSStatic
--
BVPS
5.16
P/B
2.34
HK Shares
151.54M
Dividend YieldTTM
--
DividendTTM
--
Shares
323.19M
Min lot size
100
Currency
HKD

Daily Events

  1. Nov, 16

    Bao Pharma-B opened lower at HK$10.01 but reversed to close at HK$12.08, up 15.71%, swinging from an intraday low of HK$9.99 to a session high of HK$12.05 on HK$73.8 million of turnover. The driver remains the continued digestion of BJ045's IND approval and the chairman's stake purchase, lifting the shares about 15% for the week and onto Hong Kong's top-10 gainers list. The fundamentals cut the other way: Q2 2026 revenue was only HK$5.70 million, down 75.21% year on year, while the net loss of HK$88.76 million narrowed 11.52%. At HK$12.08 the stock has just reclaimed its MA20 of HK$8.884 yet still sits below the MA60 of HK$12.109, 94.14% below the 24 February high of HK$206 and down 82.67% year to date, though 86.56% above the 22 October low of HK$6.475. Revenue halving while losses persist leaves the durability of the rebound dependent on pipeline progress.

  2. Nov, 13

    Bao Pharma-B reversed early gains to close at HK$10.42, down 8.6%, giving back part of last week's advance driven by BJ045 IND clearance and the chairman's open-market share purchase; the stock touched HK$11.69 at 09:33 before sliding to HK$10.30 by 15:17. Turnover reached 4.87 million shares worth HK$53.71 million, a 3.21% turnover rate. The close sits above the MA20 of HK$8.768 but below the MA60 of HK$12.178, down 85.05% year-to-date, 94.94% below the HK$206 high of 24 February, yet 60.93% above the HK$6.475 low of 22 October. Q2 2026 revenue was HK$5.70 million, down 75.21% year-on-year, while the net loss of HK$88.76 million narrowed 11.52% and loss per share was HK$0.2723; with negative earnings the PE stands at -7.99 and PB at 2.02. Though single-week declines of 18.85% earlier in this cycle show how volatile the register remains.

  3. Nov, 12

    Bao Pharma-B opened lower, rallied through the afternoon and then pared gains, closing at HK$11.37 for a 20.8% advance as BJ045's clinical trial clearance and the chairman's stake purchase kept circulating in weekly recaps; the stock spiked to HK$13.21 at 15:17 BJ from a morning low of HK$9.28, with turnover swelling to HK$193 million and a turnover rate of 11.13%. Fundamentals remain under pressure: Q2 2026 revenue was just HK$5.70 million, down 75.21% year on year, while the net loss of HK$88.76 million narrowed 11.52%, EPS came in at -HK$0.2723 and ROE at -21.22%. The price now sits above the MA20 of HK$8.735 but below the MA60 of HK$12.274, down 83.69% year to date and 94.48% below the February 24 52-week high of HK$206, though still 75.6% above the October 22 low of HK$6.475. Though the rebound rests on a single pipeline event and insider buying, with no visible recovery on the revenue line.

  4. Nov, 11

    Bao Pharma-B staged a spike-and-fade session: it opened at HK$9.58, touched HK$10.08 in the morning, then gave back gains to close at HK$9.415, up 2.56% from the prior HK$9.18 close on 3.31 million shares and HK$31.7 million turnover, as residual momentum from BJ045 IND clearance and the chairman's stake purchase carried into a week that had earlier added nearly 10%. Fundamentals cut the other way: Q2 2026 revenue was only HK$5.70 million, down 75.21% year on year, with a net loss of HK$88.76 million and a -1556.3% net margin, though the loss narrowed 11.5% and EPS was -HK$0.2723. At HK$9.415 the stock sits 95.43% below its 52-week high of HK$206 and is down 86.49% year to date; it holds above the 20-day MA of HK$8.67 but below the 60-day MA of HK$12.36, with PB at 1.82x. Still, the price remains 45.41% above the 22 October low of HK$6.475, and small-cap biotech swings stay wide.

  5. Nov, 6

    Bao Pharma-B opened lower, spiked to HK$9.685 in the morning, then faded through the afternoon to HK$8.725 and closed at HK$8.78, down 5.18% from the previous close of HK$9.26; turnover was HK$44.4 million. The move came after an earlier 12% jump linked to China NMPA approval of the BJ045 injection IND and Chairman Liu Yanjun’s purchases of 263,300 shares over three days for about HK$2.0243 million, plus 102,100 shares at roughly HK$7.44 each. Q2 2026 revenue was HK$5.703 million, down 75.21% year on year, and the net loss was HK$88.756 million, while EPS improved 21.82% year on year but stayed negative. At HK$8.78 the stock is below its 20-day MA of HK$8.946 and 60-day MA of HK$12.743, down 87.4% year to date and 95.74% below the 52-week high of HK$206, though it remains 35.6% above the 52-week low of HK$6.475. Its market capitalization is about HK$2.84 billion, with a negative PE of -6.74 and PB of 1.70. The intraday high at 09:44 BJ time failed to hold, and the afternoon low at 13:59 BJ time marked the weakest point.

News